Lansoprazole Pellets 8.5%

Lansoprazole Pellets 8.5%
Product Description

We Murli Krishna Pharma specialised in the manufacture of Pharmaceutical Pellets/ Micro Pellets / Granules and MUPS.We manufacture Lansoprazole Pellets 8.5%( Product complies to USP) Particle size:  ( 14 #18), ( 16 #20) and ( 30 #80) Comparative Dissolution:  The profile matches to the innovator profile.

Murli Krishna Pharma Pvt. Ltd.

  • IN
  • 2016
    On CPHI since
  • 2
    Certificates
  • 250 - 499
    Employees
Company types
Manufacturer/Innovator
Primary activities
Custom Manufacturing/Custom Synthesis
Specifications

Murli Krishna Pharma Pvt. Ltd.

  • IN
  • 2016
    On CPHI since
  • 2
    Certificates
  • 250 - 499
    Employees
Company types
Manufacturer/Innovator
Primary activities
Custom Manufacturing/Custom Synthesis

More Products from Murli Krishna Pharma Pvt. Ltd. (27)

  • TACROLIMUS MICRO PELLETS 5%W/W

    Product TACROLIMUS MICRO PELLETS 5%W/W

    TACROLIMUS MICRO PELLETS 5%W/W: (Lansoprazole Enteric Coated pellets 5% w/w). 

    FILL WEIGHT:
     

    For 5 mg capsule: 100 mg pellets filled in SIZE 4 capsule. 1 kg of Pellets can be filled in 10000 capsules /kg pellets.

     

     
    ...
  • TAMSULOSIN HCL SR PELLETS

    Product TAMSULOSIN HCL SR PELLETS

    Category - Alpha Blockers
  • Venlafaxine ER Pellets

    Product Venlafaxine ER Pellets

    Venlafaxine is a selective serotonin nor epinephrine uptake inhibitor antidepressant which is used to treat major depressive disorder, anxiety and panic disorder.
  • CLARITHROMYCIN MICRO PELLETS 27.5%W/W :(CLARITHROMYCIN Enteric Coated pellets 27.5%w/w)

    Product CLARITHROMYCIN MICRO PELLETS 27.5%W/W :(CLARITHROMYCIN Enteric Coated pellets 27.5%w/w)

    Physical Specifications: White to off white spherical pellets, Pellets Size: ASTM 30#80. Release specification: As per latest USP std, including additional parameters i.e. Related Substances (RS/impurities) and Microbiological (Ready To Fill size 0 Capsule, for Hard Gelatin Capsule ...
  • ITRACONAZOLE PELLETS 22% W/W:

    Product ITRACONAZOLE PELLETS 22% W/W:

    ITRACONAZOLE PELLETS 22% W/W:

    Specifications: White to off white spherical pellets,
    Pellets Size:  ASTM16#20: 
    Release specification: As per latest USP std.
    Fill Weight: 
    For 100mg capsule: 455mg pellets filled in SIZE 0 capsules. 1 kg of Pellets can ...
  • LANSOPRAZOLE Micro PELLETS 12.5%W/W: (Lansoprazole Enteric Coated Micro pellets 12.5%)

    Product LANSOPRAZOLE Micro PELLETS 12.5%W/W: (Lansoprazole Enteric Coated Micro pellets 12.5%)

    LANSOPRAZOLE Micro PELLETS 12.5%W/W: (Lansoprazole Enteric Coated Micro pellets 12.5%)

    Physical Specifications: White to off while spherical pellets, Pellets Size: ASTM 30#50, ASTM 25#50

    Release specification: As per latest USP std. including additional parameters i.e. ...
  • Omeprazole PELLETS 8.5%W/W: (OmeprazoleEnteric Coated pellets 8.5%w/w)

    Product Omeprazole PELLETS 8.5%W/W: (OmeprazoleEnteric Coated pellets 8.5%w/w)

    Omeprazole PELLETS 8.5%W/W: (OmeprazoleEnteric Coated pellets 8.5%w/w)


    Physical Specifications: 

    White to off while spherical pellets, Pellets Size: ASTM 14#18.

    Release specification: As per latest USP std. including additional parameters i.e. Related...
  • Azithromycin Taste Masked Pellets

    Product Azithromycin Taste Masked Pellets

    The objective of developing Azithromycin taste masked micro pellets (Multiple unit particulate system i.e. MUPS) by aqueous technology is to fill the micro pellets in to capsule, are compressed into tablet and also are constituted to make the oral suspension.
  • Brinzolamide

    Product Brinzolamide

    MKPPL developed a Nano particle based matrix which can deliver hydrophilic as well as hydrophobic drugs using a combination of hydrophilic and hydrophobic excipients as a clear solution. This cogent use of excipients ensures that the drug is absorbed optimally and the Nano particles ensure that the dru...
  • Budesonide

    Product Budesonide

    There is a potential for the development of inhalation medicines in lipid Nano particles to possess controlled release properties. MKPPL’s Budesonide suspension has been developed in a complete aqueous base using a couple of specialized solubilizers which also helps in the Nano encapsulation of the drug.
  • Dexlansoprazole Pellets

    Product Dexlansoprazole Pellets

    The pharmaceutical form of dexlansoprazole is based on the unique technology of modified dual release. The active ingredient is released in two phases at different pH values and with a time interval. Consequently, the drug achieves two peak concentrations in the blood, and the total serum concentration...
  • Duloxetine

    Product Duloxetine

    The objective is to develop Duloxetine DR pellets by aqueous technology. Pellets developed by aqueous technology have advantage of avoiding the use of organic solvents

Murli Krishna Pharma Pvt. Ltd. resources (1)